PMID- 27578132 OWN - NLM STAT- MEDLINE DCOM- 20171009 LR - 20231111 IS - 1933-2874 (Print) IS - 1876-4789 (Linking) VI - 10 IP - 4 DP - 2016 Jul-Aug TI - Poly is more effective than monounsaturated fat for dietary management in the metabolic syndrome: The muffin study. PG - 996-1003 LID - S1933-2874(16)30192-1 [pii] LID - 10.1016/j.jacl.2016.04.011 [doi] AB - BACKGROUND: The metabolic syndrome (MetS) is highly prevalent and associated with an increased risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Lifestyle recommendations to treat MetS often include the replacement of saturated fats (SFAs) and monosaccharides with unsaturated fat. However, it is unclear whether metabolic parameters will improve more when the saturated fat in American Heart Association (AHA) diets is replaced with higher concentrations of monounsaturated or polyunsaturated fatty acids (MUFA or PUFA). OBJECTIVE: To test the hypothesis that an AHA diet enriched in MUFA improves lipoprotein lipids, insulin resistance, inflammation, and endothelial function to a greater extent than a diet enriched in PUFA in middle-aged men and women with MetS. METHODS: A prospective, open-label, parallel group design with randomization to a hypocaloric MUFA or PUFA-enriched diet after weight stabilization on an AHA step I diet. Participants consumed 3 MUFA-enriched or PUFA-enriched muffins daily with additional supplementation as required to ensure 25%-50% increases in dietary fat intake from these sources at the expense of SFA and the opposing unsaturated fat. Changes in MetS components were measured at baseline and after 6 months of dietary intervention. RESULTS: Thirty-nine participants (mean age, 60.8 years; 79% African-American, 60% women) with MetS completed the 6-month study. Compared to baseline, assignment to either MUFA (n = 23) or PUFA (n = 16) both were associated with weight loss (MUFA: -2.3 +/- 1 kg, P = .06; PUFA: -4.6 +/- 2 kg; P = .002), but PUFA was also associated with reductions in triglycerides (TG) (-30 +/- 18 mg/dL, P = .02), systolic blood pressure (BP) (-7 +/- 3 mm Hg, P = .01), diastolic BP (DBP) (-4 +/- 2 mm Hg, P = .01) and improved flow mediated dilation (FMD) (7.1% +/- 1.8% vs 13.6% +/- 2%, absolute increase; P = .0001). When compared to MUFA treatment, PUFA intervention was associated with reduced TG (P = .04) and DBP (P = .07) as well as increased FMD (P = .04) even after adjustment for changes in weight. There was no effect on total cholesterol, low-density lipoprotein cholesterol, glucose, high-sensitivity C-reactive protein (hs-CRP), or other inflammatory proteins. Overall, 25% (4 of 16) assigned to PUFA and 13% (3 of 23) to MUFA converted to non-MetS status. CONCLUSION: Substitution of SFA with PUFA in patients with MetS is associated with greater reductions in TG and improvement in endothelial function than MUFA that is independent of weight loss. These preliminary findings raise the possibility that PUFA may be the unsaturated fat of choice to reduce cardiometabolic risk in patients with MetS. CI - Copyright (c) 2016 National Lipid Association. Published by Elsevier Inc. All rights reserved. FAU - Miller, Michael AU - Miller M AD - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA; Division of Cardiology, University of Maryland School of Medicine, Baltimore, MD, USA; University of Maryland School of Medicine, Baltimore, MD, USA; Geriatric Research Education and Clinical Center, Veterans Affairs Medical Center, Baltimore, USA. Electronic address: mmiller@medicine.umaryland.edu. FAU - Sorkin, John D AU - Sorkin JD AD - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; University of Maryland School of Medicine, Baltimore, MD, USA; Geriatric Research Education and Clinical Center, Veterans Affairs Medical Center, Baltimore, USA; Division of Gerontology and Geriatric Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Mastella, Laura AU - Mastella L AD - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; University of Maryland School of Medicine, Baltimore, MD, USA; Division of Gerontology and Geriatric Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Sutherland, Aimee AU - Sutherland A AD - University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Rhyne, Jeffrey AU - Rhyne J AD - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Division of Cardiology, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Donnelly, Patrick AU - Donnelly P AD - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Simpson, Kathy AU - Simpson K AD - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Geriatric Research Education and Clinical Center, Veterans Affairs Medical Center, Baltimore, USA; Division of Gerontology and Geriatric Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Goldberg, Andrew P AU - Goldberg AP AD - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; University of Maryland School of Medicine, Baltimore, MD, USA; Geriatric Research Education and Clinical Center, Veterans Affairs Medical Center, Baltimore, USA; Division of Gerontology and Geriatric Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. LA - eng GR - I01 CX000147/CX/CSRD VA/United States GR - P30 AG028747/AG/NIA NIH HHS/United States GR - P30 DK072488/DK/NIDDK NIH HHS/United States GR - T35 DK095737/DK/NIDDK NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20160506 PL - United States TA - J Clin Lipidol JT - Journal of clinical lipidology JID - 101300157 RN - 0 (Dietary Fats, Unsaturated) RN - 0 (Fatty Acids, Monounsaturated) RN - 0 (Fatty Acids, Unsaturated) RN - 0 (Lipoproteins) SB - IM MH - Adult MH - Aged MH - Dietary Fats, Unsaturated/*pharmacology/therapeutic use MH - Endothelium, Vascular/drug effects/pathology MH - Fatty Acids, Monounsaturated/*pharmacology/therapeutic use MH - Fatty Acids, Unsaturated/*pharmacology/therapeutic use MH - Female MH - Humans MH - Insulin Resistance MH - Lipoproteins/blood MH - Male MH - Metabolic Syndrome/blood/complications/*diet therapy/pathology MH - Middle Aged MH - Overweight/complications PMC - PMC5010036 MID - NIHMS784671 OTO - NOTNLM OT - African Americans OT - Diet OT - Endothelial function OT - FMD OT - Lipoproteins OT - MUFA OT - Metabolic syndrome OT - Muffins OT - PUFA OT - Triglyceride EDAT- 2016/09/01 06:00 MHDA- 2017/10/11 06:00 PMCR- 2017/07/01 CRDT- 2016/09/01 06:00 PHST- 2016/03/02 00:00 [received] PHST- 2016/04/26 00:00 [accepted] PHST- 2016/09/01 06:00 [entrez] PHST- 2016/09/01 06:00 [pubmed] PHST- 2017/10/11 06:00 [medline] PHST- 2017/07/01 00:00 [pmc-release] AID - S1933-2874(16)30192-1 [pii] AID - 10.1016/j.jacl.2016.04.011 [doi] PST - ppublish SO - J Clin Lipidol. 2016 Jul-Aug;10(4):996-1003. doi: 10.1016/j.jacl.2016.04.011. Epub 2016 May 6.